ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company, has successfully raised an aggregate $470 million of equity and debt financing in 2021, with $300 million in new debt financing from NantCapital, LLC. With this new financing from ImmunityBio’s founder, Executive Chairman and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, on December 17, 2021, the company is now well positioned to pursue its late-stage clinical portfolio, expand large-scale GMP manufacturing capacity, and advance recruitment of a commercial organization in the urology market.
Greenlight Re Innovations Announces Investment In Short-Term Rental Insurance Startup Safely
Greenlight Re Innovations ("GRI"), part of Greenlight Capital Re, Ltd. (NASDAQ:GLRE) ("Greenlight Re" or the "Company"), has announced an investment in SafelyStay, Inc
